Novo-backed MapLight valued at $787 million after shares jump in Nasdaq debut
By Arasu Kannagi Basil (Reuters) -MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company to go public under a rarely used regulatory provision since the start of the U.S. government shutdown. Shares of the Redwood City, California-based company, which is developing treatments for central nervous system…